Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity

In patients with heart failure with preserved ejection fraction and obesity, semaglutide (2.4 mg) led to greater reductions in symptoms and physical limitations and greater improvements in exercise function than placebo.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2023-09, Vol.389 (12), p.1069-1084
Hauptverfasser:	Kosiborod, Mikhail N., Abildstrøm, Steen Z., Borlaug, Barry A., Butler, Javed, Rasmussen, Søren, Davies, Melanie, Hovingh, G. Kees, Kitzman, Dalane W., Lindegaard, Marie L., Møller, Daniél V., Shah, Sanjiv J., Treppendahl, Marianne B., Verma, Subodh, Abhayaratna, Walter, Ahmed, Fozia Z., Chopra, Vijay, Ezekowitz, Justin, Fu, Michael, Ito, Hiroshi, Lelonek, Małgorzata, Melenovsky, Vojtech, Merkely, Bela, Núñez, Julio, Perna, Eduardo, Schou, Morten, Senni, Michele, Sharma, Kavita, Van der Meer, Peter, von Lewinski, Dirk, Wolf, Dennis, Petrie, Mark C
Format:	Artikel
Sprache:	eng
Schlagworte:	Antidiabetics Body weight loss C-reactive protein Cardiology Cardiomyopathy Clinical Medicine Clinical Medicine General Congestive heart failure Diabetes Diet Ejection fraction Endocrinology Gastroenterology Gastrointestinal surgery Glucagon-Like Peptides - adverse effects Glucagon-Like Peptides - therapeutic use Heart Failure Heart Failure - complications Heart Failure - drug therapy Heart Failure - physiopathology Humans Intravenous therapy Nutrition Obesity Obesity - complications Overweight Patients Peptides Placebos Quality of life Statistical analysis Stroke Volume Weight control
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In patients with heart failure with preserved ejection fraction and obesity, semaglutide (2.4 mg) led to greater reductions in symptoms and physical limitations and greater improvements in exercise function than placebo.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa2306963